Skip to main content
Menu

The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)

The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN) is a consortium dedicated to the advancement of treatments, diagnostic markers, and outcome measures of leukodystrophies. The consortium is comprised of patient advocacy partners, industry stakeholders, and scientists. Their research involves a range of disorders, including Aicardi–Goutières syndrome (AGS), Metachromatic Leukodystrophy (MLD), Pelizaeus Merzbacher Disease (PMD), and more.

GLIA-CTN

Study Participants

Biospecimen collection is ongoing. Currently, biospecimens are available from more than 70 individuals.

Available Data

Please visit https://glia-ctn.rarediseasesnetwork.org/ for more information regarding available clinical data. If you have further questions regarding clinical data, please contact Omar Sherbini.

Available Biospecimens

Plasma and serum.

Samples were collected through the GLIA-CTN research sites thanks to the generous contributions of patients and families within the leukodystrophy community. The GLIA-CTN is part of the Rare Diseases Clinical Research Network (RDCRN) and is funded under U54NS115052 as a collaboration between the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Neurological Disorders and Stroke (NINDS).